3,4-dihydroxyphenylglycol has been researched along with Fragile X Syndrome in 14 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (7.14) | 29.6817 |
2010's | 12 (85.71) | 24.3611 |
2020's | 1 (7.14) | 2.80 |
Authors | Studies |
---|---|
Hien, A; Huber, KM; Liu, B; Molinaro, G; Richter, JD | 1 |
Mackie, K; Min, KT; Straiker, A | 1 |
Ashwood, P; Basuta, K; Careaga, M; Hagerman, RJ; Noyon, T; Tassone, F; Van de Water, J | 1 |
Achuta, VS; Castrén, ML; Grym, H; Kärkkäinen, V; Koistinaho, J; Louhivuori, V; Putkonen, N; Roybon, L | 1 |
Banke, TG; Lundbye, CJ; Toft, AK | 1 |
Hoeffer, CA; Klann, E; McBride, SM; Miyawaki, T; Sharma, A; Takayasu, Y; Zukin, RS | 1 |
Bassell, GJ; Chan, CB; Gross, C; Nakamoto, M; Warren, ST; Yao, X; Ye, K; Yim, SY | 1 |
Chen, SQ; Den, WY; Fan, HX; Gao, MM; Jiang, T; Su, T; Sun, WW; Yi, YH; Zhao, QH | 1 |
Bongmba, OY; Butler, K; Elhardt, ME; Martinez, LA; Tejada-Simon, MV | 1 |
Corbin, JG; Huntsman, MM; Olmos-Serrano, JL; Paluszkiewicz, SM | 1 |
Birnbaum, SG; Collins, KA; Gibson, JR; Guo, W; Hays, SA; Hu, JH; Huber, KM; Ronesi, JA; Tsai, NP; Worley, PF | 1 |
Bozdagi, O; Buxbaum, JD; Dorr, N; Pilorge, M; Sakurai, T; Takahashi, N | 1 |
Alvarez-Dieppa, AC; Bhattacharya, A; Kaphzan, H; Klann, E; Murphy, JP; Pierre, P | 1 |
Huber, KM; Nosyreva, ED | 1 |
14 other study(ies) available for 3,4-dihydroxyphenylglycol and Fragile X Syndrome
Article | Year |
---|---|
Ribosome profiling in mouse hippocampus: plasticity-induced regulation and bidirectional control by TSC2 and FMRP.
Topics: Animals; Fragile X Mental Retardation Protein; Fragile X Syndrome; Hippocampus; Methoxyhydroxyphenylglycol; Mice, Inbred C57BL; Neuronal Plasticity; Peptide Elongation Factor 2; Protein Binding; Protein Biosynthesis; Receptors, Metabotropic Glutamate; Ribosomes; RNA 5' Terminal Oligopyrimidine Sequence; Signal Transduction; Tuberous Sclerosis Complex 2 Protein | 2020 |
Fmr1 deletion enhances and ultimately desensitizes CB(1) signaling in autaptic hippocampal neurons.
Topics: Adenosine; Animals; Baclofen; Data Interpretation, Statistical; Electrophysiological Phenomena; Excitatory Postsynaptic Potentials; Fragile X Mental Retardation Protein; Fragile X Syndrome; GABA Agonists; Hippocampus; Methoxyhydroxyphenylglycol; Mice; Mice, Knockout; Neurons; Receptor, Cannabinoid, CB1; Receptors, Metabotropic Glutamate; Synapses | 2013 |
Group I metabotropic glutamate receptor mediated dynamic immune dysfunction in children with fragile X syndrome.
Topics: Case-Control Studies; Cells, Cultured; Child; Child, Preschool; Cytokines; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Fragile X Mental Retardation Protein; Fragile X Syndrome; Humans; Leukocytes, Mononuclear; Lipopolysaccharides; Male; Methoxyhydroxyphenylglycol; Mitogens; Phytohemagglutinins; Pyridines; Receptors, Metabotropic Glutamate; Statistics, Nonparametric; Thiazoles; Trinucleotide Repeat Expansion | 2014 |
Metabotropic glutamate receptor 5 responses dictate differentiation of neural progenitors to NMDA-responsive cells in fragile X syndrome.
Topics: Animals; Cell Differentiation; Cerebral Cortex; Disease Models, Animal; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Female; Fragile X Syndrome; Humans; Male; Methoxyhydroxyphenylglycol; Mice; Mice, Inbred C57BL; Mice, Knockout; N-Methylaspartate; Neural Stem Cells; Pyridines; Receptor, Metabotropic Glutamate 5 | 2017 |
Dysregulated NMDA-Receptor Signaling Inhibits Long-Term Depression in a Mouse Model of Fragile X Syndrome.
Topics: Age Factors; Animals; Biophysics; CA3 Region, Hippocampal; Disease Models, Animal; Electric Stimulation; Excitatory Amino Acid Agents; Excitatory Postsynaptic Potentials; Fragile X Mental Retardation Protein; Fragile X Syndrome; In Vitro Techniques; Long-Term Synaptic Depression; Male; Methoxyhydroxyphenylglycol; Mice; Mice, Inbred C57BL; Mice, Knockout; Receptors, N-Methyl-D-Aspartate; Signal Transduction; Synapses | 2016 |
Dysregulation of mTOR signaling in fragile X syndrome.
Topics: Adaptor Proteins, Signal Transducing; Animals; CA1 Region, Hippocampal; Carrier Proteins; Cell Cycle Proteins; Cognition Disorders; Disease Models, Animal; Eukaryotic Initiation Factor-4A; Eukaryotic Initiation Factors; Excitatory Postsynaptic Potentials; Fragile X Mental Retardation Protein; Fragile X Syndrome; Gene Expression Regulation; Immunoprecipitation; In Vitro Techniques; Long-Term Synaptic Depression; Methoxyhydroxyphenylglycol; Mice; Mice, Knockout; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Phosphoproteins; Phosphorylation; Receptors, Metabotropic Glutamate; Serine; Signal Transduction; Sirolimus | 2010 |
Excess phosphoinositide 3-kinase subunit synthesis and activity as a novel therapeutic target in fragile X syndrome.
Topics: Analysis of Variance; Animals; Cells, Cultured; Class I Phosphatidylinositol 3-Kinases; Dendrites; Disease Models, Animal; Embryo, Mammalian; Enzyme Inhibitors; Excitatory Amino Acid Antagonists; Fragile X Mental Retardation Protein; Fragile X Syndrome; Gene Expression Regulation, Enzymologic; Green Fluorescent Proteins; Hippocampus; Humans; Immunoprecipitation; Luminescent Proteins; Methoxyhydroxyphenylglycol; Mice; Mice, Knockout; Models, Biological; Neurons; Phosphatidylinositol 3-Kinases; Protein Subunits; Receptors, AMPA; Red Fluorescent Protein; RNA, Messenger; Synapses; Synaptosomes; Transfection | 2010 |
Early continuous inhibition of group 1 mGlu signaling partially rescues dendritic spine abnormalities in the Fmr1 knockout mouse model for fragile X syndrome.
Topics: Age Factors; Analysis of Variance; Animals; Animals, Newborn; Benzopyrans; Cells, Cultured; Dendritic Spines; Disease Models, Animal; Fragile X Mental Retardation Protein; Fragile X Syndrome; Hippocampus; Methoxyhydroxyphenylglycol; Mice; Mice, Inbred C57BL; Mice, Knockout; Neural Inhibition; Neurons; Pyridines; Receptors, Metabotropic Glutamate; Signal Transduction; Silver Staining | 2011 |
Modulation of dendritic spines and synaptic function by Rac1: a possible link to Fragile X syndrome pathology.
Topics: Aminoquinolines; Analysis of Variance; Animals; Brain; Dendrites; Dendritic Spines; Disease Models, Animal; Electric Stimulation; Excitatory Amino Acid Antagonists; Excitatory Postsynaptic Potentials; Fragile X Mental Retardation Protein; Fragile X Syndrome; Gene Expression Regulation; In Vitro Techniques; Methoxyhydroxyphenylglycol; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neurons; Patch-Clamp Techniques; Pyrimidines; rac1 GTP-Binding Protein; Signal Transduction; Silver Staining; Synapses | 2011 |
Impaired inhibitory control of cortical synchronization in fragile X syndrome.
Topics: Action Potentials; Animals; Cortical Synchronization; Fragile X Mental Retardation Protein; Fragile X Syndrome; gamma-Aminobutyric Acid; Interneurons; Male; Methoxyhydroxyphenylglycol; Mice; Mice, Inbred Strains; Mice, Knockout; Neural Inhibition; Organ Culture Techniques; Phenotype; Pyramidal Cells; Receptors, Metabotropic Glutamate; Somatosensory Cortex; Somatostatin; Synaptic Transmission | 2011 |
Disrupted Homer scaffolds mediate abnormal mGluR5 function in a mouse model of fragile X syndrome.
Topics: Analysis of Variance; Animals; Carrier Proteins; Cycloheximide; Disease Models, Animal; Electric Stimulation; Exploratory Behavior; Fragile X Mental Retardation Protein; Fragile X Syndrome; Gene Expression Regulation; Hippocampus; Homer Scaffolding Proteins; Immunoprecipitation; In Vitro Techniques; Long-Term Potentiation; Methoxyhydroxyphenylglycol; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mutation; Nerve Net; Patch-Clamp Techniques; Peptides; Physics; Protein Synthesis Inhibitors; Rats; Rats, Long-Evans; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Serine; Signal Transduction; TOR Serine-Threonine Kinases | 2012 |
Haploinsufficiency of Cyfip1 produces fragile X-like phenotypes in mice.
Topics: Adaptor Proteins, Signal Transducing; Animals; Behavior, Animal; Disease Models, Animal; DNA Copy Number Variations; Excitatory Amino Acid Antagonists; Fragile X Syndrome; Gene Order; Genotype; Haploinsufficiency; Long-Term Potentiation; Long-Term Synaptic Depression; Male; Methoxyhydroxyphenylglycol; Mice; Mice, Knockout; Nerve Tissue Proteins; Phenotype; Protein Biosynthesis; Receptors, Glutamate | 2012 |
Genetic removal of p70 S6 kinase 1 corrects molecular, synaptic, and behavioral phenotypes in fragile X syndrome mice.
Topics: Analysis of Variance; Animals; Behavior, Animal; Biophysics; Dendritic Spines; Disease Models, Animal; Electric Stimulation; Excitatory Postsynaptic Potentials; Exploratory Behavior; Extracellular Signal-Regulated MAP Kinases; Female; Fragile X Mental Retardation Protein; Fragile X Syndrome; Gene Expression Regulation; Hippocampus; In Vitro Techniques; Interpersonal Relations; Long-Term Synaptic Depression; Male; Maze Learning; Membrane Potentials; Methoxyhydroxyphenylglycol; Mice; Mice, Inbred C57BL; Mice, Transgenic; Motor Activity; Mutation; Neurons; Patch-Clamp Techniques; Phenotype; Phosphorylation; Recognition, Psychology; Ribosomal Protein S6 Kinases, 70-kDa; Rotarod Performance Test; Synapses; TOR Serine-Threonine Kinases | 2012 |
Metabotropic receptor-dependent long-term depression persists in the absence of protein synthesis in the mouse model of fragile X syndrome.
Topics: 2-Amino-5-phosphonovalerate; Animals; Anisomycin; Blotting, Western; Disease Models, Animal; Drug Interactions; Electric Stimulation; Excitatory Amino Acid Antagonists; Fragile X Mental Retardation Protein; Fragile X Syndrome; Hippocampus; In Vitro Techniques; Long-Term Synaptic Depression; Methoxyhydroxyphenylglycol; Mice; Mice, Knockout; Neurons; Protein Biosynthesis; Protein Synthesis Inhibitors; Receptors, Metabotropic Glutamate | 2006 |